Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.68 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897422 | 0.87 | HRH3 (0.68) | HRH3CARM1PRMT6DRD2 | |
| SCHEMBL1891613 | 0.84 | HRH3 (0.57) | HRH3CARM1PRMT6 | |
| SCHEMBL1813178 | 0.83 | HRH3 (0.46) | HRH3 | |
| SCHEMBL8391744 | 0.83 | HRH3 (0.67) | HRH3CARM1PRMT6GAASMN1; SMN2 | |
| SCHEMBL1283269 | 0.81 | CYP3A4 (0.48) | HRH3DRD2DRD3 | |
| SCHEMBL12803875 | 0.81 | HRH3 (0.69) | HRH3CARM1PRMT6GAASMN1; SMN2 | |
| SCHEMBL14924453 | 0.81 | HRH3 (0.69) | HRH3CARM1PRMT6GAASMN1; SMN2 | |
| SCHEMBL188648 | 0.81 | HRH3 (0.63) | HRH3CARM1PRMT6SMN1; SMN2DRD3 | |
| SCHEMBL5208517 | 0.81 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1896242 | 0.81 | HRH3 (0.49) | HRH3CARM1PRMT6DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622611-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
| WO-2004096213-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | HRH3 41/4885CARM1 1591/4885PRMT6 2270/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | HRH3 31/4885CARM1 1874/4885PRMT6 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.